EP Patent

EP2647379A1 — Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis

Assigned to Preglem SA · Expires 2013-10-09 · 13y expired

What this patent protects

The present invention is related to a combination of a steroid sulfatase inhibitor, E2MATE or EMATE, with norethindrone (NET) or norethindrone acetate (NETA) for use in the prevention or treatment of endometriosis. The present invention further relates to a method for preventing …

USPTO Abstract

The present invention is related to a combination of a steroid sulfatase inhibitor, E2MATE or EMATE, with norethindrone (NET) or norethindrone acetate (NETA) for use in the prevention or treatment of endometriosis. The present invention further relates to a method for preventing or treating endometriosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP2647379A1
Jurisdiction
EP
Classification
—
Expires
2013-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Preglem SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.